Ten Bridge Communications

We guide biotech through the big moments.

[Ten Bridge Communications @TenBridge]

Congratulations to #TBCPartner @AtalantaTx who just announced an oversubscribed Series B financing of $97 million! The funding will support the advancement of Atalanta's RNAi medicines for CNS diseases, including clinical development for its investigational therapies targeting KCNT1-related epilepsy and Huntington’s disease.

Named after the Greek heroine Atalanta, the company was founded to promote RNA interference that could silence disease-causing genes. This Nobel prize-winning science offers an opportunity to regulate genes and stop disease at its source.

We can't wait to see what the future holds for this motivated team.

[Boston Business Journal @BosBizJournal]

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic. https://t.co/I9w4VVNcWa

[Ten Bridge Communications @TenBridge]

An exciting milestone for #TBCPartner @Palleon_Pharma, who is is teaming up with @HenliusBiotech to evaluate Palleon’s E-602 + Henlius’ rituximab HANLIKANG in clinical studies for #LupusNephritis. This marks the first application of glyco-immunology in autoimmune diseases. Well done, team Palleon!

[Palleon Pharma @Palleon_Pharma]

🚀 Exciting news! Palleon and @HenliusBiotech are teaming up to clinically evaluate glycan editing for enhanced B cell depletion in #LupusNephritis. This is the first application of glyco-immunology in autoimmune diseases.

Read more in our press release: https://t.co/gPYLT3vKDp

#glycotime

[Ten Bridge Communications @TenBridge]

#TBCPartner @intelliatx presented the first disease progression data from its Phase 1 trial of nex-z in transthyretin amyloidosis, an underappreciated cause of heart failure in elderly patients, during a special scientific session in Chicago this weekend to celebrate the 100th anniversary of the American Heart Association (@American_Heart).

The data showed that nex-z has real potential to halt or even reverse the course of disease. With Phase 3 trials underway, we look forward to learning more about what Intellia’s revolutionary #CRISPR therapies can do for patients.

[Endpoints News @endpts]

Intellia says its gene editing treatment for a heart muscle disease can stabilize or improve outcomes where other treatments have only been shown to slow the disease’s progression.
https://t.co/HAUUNtfzT1

[Ten Bridge Communications @TenBridge]

Last week, TBC’ers volunteered at @communityserv, a Boston-based nonprofit that prepares nutritious meals for individuals and families facing critical and chronic illnesses.

Giving back to our community is core to our mission at Ten Bridge, and partnering with Community Servings is always an inspiring experience. We were proud to support their commitment to providing nutritious, home-delivered meals to those in need. We’re already looking forward to our next visit!

[Ten Bridge Communications @TenBridge]

Huge congratulations to #TBCPartner @VeronaPharma, whose outstanding achievements for patients with #COPD were recognized by the #FierceInnovationAwards!

Verona’s recently approved drug for the maintenance treatment of COPD is the first inhaled product with a novel mechanism of action in more than 20 years and has the potential to redefine the treatment landscape.

[Verona Pharma @VeronaPharma]

We're excited to share that Verona is a finalist for the #FierceInnovationAwards in the Biotech Innovation category!

We are committed to bringing innovative treatments to patients with #COPD and other respiratory diseases.
#FierceLifeSciencesAwards

[Ten Bridge Communications @TenBridge]

Last week #TBCPartner @intelliatx unveiled Phase 2 data from their trial of NTLA-2002 targeting hereditary angioedema (HAE), a rare disease that causes swelling attacks in various parts of the body. Data supported a functional cure for HAE - just one dose led to deep reduction of swelling attacks in patients. Excited to see this real patient impact from Intellia and all that is to come for their #CRISPR medicines!

[Ryan Cross the Science Boss @RLCscienceboss]

#CRISPR therapy cuts hereditary angioedema swelling attacks by 81% in @intelliatx's 16-week Phase 2 study.

8 of 11 patients on medium dose (being tested in Phase 3) have had zero attacks since the infusion.

Read more in my story for @endpts: https://t.co/JtKzhadYjC

[Ten Bridge Communications @TenBridge]

Congrats to #TBCPartners @C4Therapeutics, Parabilis Medicines and @Sarepta who were recipients of this year’s @BostInno Fire Awards, a recognition that is given to local companies that have achieved significant advancements over the last year – including raising funds, launching new products and supporting the local community and innovation ecosystem.

[Boston Business Journal @BosBizJournal]

This year’s Fire Awards honorees were selected based on nominations you sent in. These companies have demonstrated success in raising funds, launching new products, bringing in new customers, growing their Boston footprint and supporting the community. https://t.co/BUL4RMXQIb

[Ten Bridge Communications @TenBridge]

#TBCPartner Archon Biosciences is coming out of stealth with $20M in seed financing at an incredibly exciting time.

As this year’s Nobel Prize in Chemistry highlights, advances in protein design have created myriad of possibilities for improving human health. Archon is taking one of the most direct routes of applying this new technology by using generative protein design to transform antibodies into more effective drugs.

We’re thrilled for the Archon team and join them in celebrating this momentous occasion! Learn more about their science and team at https://t.co/yB0QoVlcSB

[Andrew Dunn @AndrewE_Dunn]

The newest David Baker startup is taking an AI twist on antibodies to make a new therapeutic modality, antibody cages

$20 million seed round to start: https://t.co/FzhQQvg43K

[Ten Bridge Communications @TenBridge]

Congratulations to Li Peng, Chief Scientific Officer of #TBCPartner @Palleon_Pharma, who was named to the 2024 @PharmaVoice 100 list! Li is a trailblazer in the growing field of glyco-immunology, shaping Palleon's approach and increasing enthusiasm for others to learn more about the science behind it.

[Palleon Pharma @Palleon_Pharma]

We’re proud to share that our CSO, Li Peng, was named to this year's @PharmaVoice 100 list!

Li is recognized for her work to progress the uncharted field of glyco-immunology, and for her tenacious spirit that has shaped and improved our platform. Read more: https://t.co/44snl0XUvn

[Ten Bridge Communications @TenBridge]

Today #TBCPartner @SeaportTx , a founded entity of fellow #TBCPartner @PureTechH has successfully closed a Series B financing of $225 million led by @generalatlantic to progress its clinical-stage pipeline of neuropsychiatric medicines. Seaport is focusing on programs for major depressive disorder, generalized anxiety and mood disorders, one of the most challenging therapeutic areas for drug development.

[SeaportTx @SeaportTx]

Today we announced a $225M oversubscribed Series B led by @generalatlantic. Proud to partner w/an incredible group of investors who share our commitment of delivering better medicines to those w/ #depression, #anxiety & other #neuropsychiatric disorders: https://t.co/o9ZvAUQron

[Ten Bridge Communications @TenBridge]

Congratulations to David Baker for winning the Nobel Prize in Chemistry and, in the words of the Royal Swedish Academy of Sciences, achieving the “almost impossible feat of building entirely new kinds of proteins.”

Engineering proteins with novel shapes and functions unlocks nearly endless possibilities to create more effective medicines, diagnostics, and sensors. At Ten Bridge, we’re thrilled to be working alongside a biotech co-founded by David, to help translate his science and create the next generation of computationally designed drugs.

[The Nobel Prize @NobelPrize]

Proteins generally consist of 20 different amino acids, which can be described as life’s building blocks. In 2003, David Baker succeeded in using these blocks to design a new protein that was unlike any other protein. Since then, his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors.

Earlier this week it was announced that Baker was awarded the 2024 chemistry prize for his work on computational protein design.

Discover more about this year's chemistry prize: https://t.co/KvftI77NdM

#NobelPrize

[Ten Bridge Communications @TenBridge]

Congratulations to #TBCPartner @CityTx_ who launched last week with a $135 million Series A to improve and expand the therapeutic reach of RNAi-based medicines!

[City Therapeutics @CityTx_]

Welcome to CityTx! We announce our launch today w/ a mission to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases. Learn more: https://t.co/MJeQksrLpA

[Ten Bridge Communications @TenBridge]

We were thrilled to be joined by @endpts co-founder @arsalanarif at our team offsite this week. Thank you, Arsalan, for sharing your valuable insights and perspectives with us on the growth of Endpoints and what's to come in the industry.

[Ten Bridge Communications @TenBridge]

Congrats to #TBCPartner @PureTechH on the FDA approval of Cobenfy (formerly KarXT), originally invented by the team at PureTech! This drug marks the first new innovation for the treatment of #schizophrenia in over 50 years.

Read more: https://t.co/5Q3BfeG9Dz

[Ten Bridge Communications @TenBridge]

Sincerest congratulations to #TBCPartners @capstantx and @SeaportTx, who last night were named as two of this year’s #Endpoints11!

https://t.co/JF3fGOfwyd

[Ten Bridge Communications @TenBridge]

#TBCPartner @imvax_inc's CEO John Furey recently connected with @AliGormanTV to discuss what’s on the horizon for the company and the progress it is making in its ongoing Phase 2 clinical trail in glioblastoma. Check out the interview below to learn more about what Imvax is doing to progress a potential new treatment for this vastly underserved treatment population.

@BiotechTVHQ

[Imvax, Inc. @imvax_inc]

CEO John Furey joined @AliGormanTV of @BiotechTVHQ at Imvax HQ to discuss the latest on our lead candidate, IGV-001, and the promise that it holds for the treatment of newly diagnosed #glioblastoma.

[Ten Bridge Communications @TenBridge]

#TBCPartner AIRNA today announced the successful closing of an oversubscribed $60 million financing round, an important step forward for their work to advance a broad RNA editing pipeline, including their lead program for alpha-1 antitrypsin deficiency (AATD). Read more in today’s piece by @AlexWestchester at @GENbio:

[Genetic Engineering & Biotechnology News @GENbio]

RNA Editing Therapy Developer Closes $60M Series A Financing

AIRNA, a developer of RNA editing therapies whose lead program targets AATD, has closed an oversubscribed $60 million Series A financing. Learn more: https://t.co/PNRhICpYKY

[Ten Bridge Communications @TenBridge]

Exciting news for #TBCPartner @SOTIO which recently announced its latest partnership, further expanding its next-generation antibody-drug conjugate pipeline for the treatment of solid tumors. This marks SOTIO’s fourth partnership for the development of ADCs – a highly specific and potent treatment class.

[SOTIO @SOTIO]

Today we announced a research collaboration and exclusive licensing agreement with @Biocytogen to expand our #ADC pipeline. This agreement enables us to license multiple fully human bispecific antibodies generated with Biocytogen’s RenLite® platform for developing next-generation ADCs targeting solid #tumors. Read more in our press release: https://t.co/STtxumvqAV

[Ten Bridge Communications @TenBridge]

Last week, some members of our team volunteered with the @CharlesRiver Watershed Association to remove invasive water chestnuts from the Charles River here in Massachusetts.

Water chestnuts are an invasive aquatic plant found in the Charles River. They are rosette shaped and fast growing, thus blocking out other life in the river. Thanks to the CRWAs efforts, they have removed over 100 tons of water chestnuts from the Charles.

Our team helped remove another 106 baskets of water chestnuts. Well done team, and thank you to the CRWA for another amazing volunteer experience!

[Ten Bridge Communications @TenBridge]

Earlier this year, we had the privilege of partnering with #TBCPartner Clasp Therapeutics to launch their company and announce their Series A. Clasp is developing off-the-shelf precision immuno-oncology therapeutics to target hard-to-treat tumors with absolute specificity. Their launch was incredibly impactful, receiving some great recognition across key media outlets. Some of the communications highlights included:

- 19 feature stories
- 37 total pieces of coverage
- Gained 2,500 LinkedIn followers in the first 24 hours following launch

Learn more about our collaboration with Clasp in our recent case study: https://t.co/pSv29DUd3Z